CMBA
CBIO

C.M. Bidwell & Associates’s Crescent Biopharma CBIO Stock Holding History

C.M. Bidwell & Associates’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14
Closed -$21K – 417
2018
Q3 		$21K Buy
+14
New +$21.2K 0.02% 282

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

C.M. Bidwell & Associates's CBIO Position: Q4 2018 in Review

C.M. Bidwell & Associates sold out of Crescent Biopharma (CBIO) in Q4 2018, closing a stake of 14 shares — an estimated $21K sold.

C.M. Bidwell & Associates first reported a position in CBIO in Q3 2018 and held it in 1 quarter. The position peaked at $21K in Q3 2018. 81 funds tracked by Wall St. Rank hold CBIO as of Q4 2018.

  • C.M. Bidwell & Associates reported no remaining Crescent Biopharma position as of Q4 2018 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 14 Crescent Biopharma shares in Q4 2018, an estimated $21K.
  • C.M. Bidwell & Associates first reported a position in Crescent Biopharma in Q3 2018 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Crescent Biopharma position peaked at $21K in Q3 2018.
  • 81 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2018, filed 14 Feb 2019.